On the evening of April 26, Huluwa (605199) announced its 2023 annual results announcement. It achieved annual revenue of 1,905 billion yuan, an increase of 25.75%; realized net profit attributable to shareholders of listed companies of 106 million yuan, an increase of 24.29% over the previous year; and realized net profit of 81.8068 million yuan attributable to shareholders of listed companies after deducting non-operating profit and loss, an increase of 20.21% over the previous year. The company plans to distribute a cash dividend of 1.25 yuan (tax included) to all shareholders for every 10 shares, for a total cash dividend of 5 million 13,600 yuan, accounting for 46.96% of net profit due to mother in 2023. The report points out that the company continues to increase investment in research and development, optimize the R&D system, and continuously expand its reserves of children's drug varieties. Focusing on the treatment fields of children's digestive system, respiratory system, anti-infection, anti-virus, etc., the company actively broadens channels of foreign cooperation, increases efforts to transform achievements, and lays out innovative products for future sustainable development. Currently, the company is developing 128 varieties, of which children's drugs account for about half, showing strong innovation.